Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt-Reference-Cited by-同舟云学术

Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt

Published:2017-11-29 Issue:3 Volume:47 Page:421-431
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Omar H.¹^ORCID,El Akel W.¹,Elbaz T.¹,El Kassas M.²^ORCID,Elsaeed K.³,El Shazly H.⁴,Said M.¹,Yousif M.⁵,Gomaa A. A.⁶,Nasr A.⁷,AbdAllah M.⁸,Korany M.⁹,Ismail S. A.¹⁰,Shaker M. K.³,Doss W.¹,Esmat G.¹,Waked I.⁴^ORCID,El Shazly Y.³

Affiliation:

1. Faculty of Medicine; Cairo University; Cairo Egypt

2. Faculty of Medicine; Helwan University; Cairo Egypt

3. Faculty of Medicine; Ain Shams University; Cairo Egypt

4. National Liver Institute; Menoufiya University; Shebeen EL Kom Egypt

5. Faculty of Medicine; Zagazig University; Zagazig Egypt

6. Faculty of Medicine; Fayoum University; Fayoum Egypt

7. Faculty of Medicine; Assiut University; Assiut Egypt

8. National Research Center; Cairo Egypt

9. National Committee for Control of Viral Hepatitis; Cairo Egypt

10. National Hepatology and Tropical Medicine Research Institute; Cairo Egypt

Publisher